Back to list
Dr. John H Abeles
Zimbabwe
Startup / Entrepreneur
Position / Role
Chairman ; Board Director; Consultant; Investor
Field of Occupation
Medical
Company Details
Company
Northlea Partners LLLP ; MedVest Group
Region of Activities
North America
Medical field
Immunology
Short description of the company / technology
JOHN H. ABELES MD
Dr Abeles was born in 1945 in Rhodesia (now Zimbabwe). He received his Medical degree as well as a degree in Physiology from the University of Birmingham, England, in 1969.
He practised Medicine in London, before joining the Pharmaceutical Industry in late 1971 as a Senior Medical Executive, with Sterling Drug in the UK, and then from 1973 with Pfizer Inc and Revlon Health Care in the USA.
In 1975 he became the first, full-time Wall Street health-care analyst with MD qualifications, at Kidder Peabody, until 1980 when he formed MedVest Inc and later Northlea Partners.
During this time he had a part-time, general internal medical practice in Westport, Connecticut.
Since March 1982, Dr. Abeles has been the Founder, Sole Investor and General Partner of Northlea Partners Ltd., a venture and private capital, family-office partnership headquartered in Boca Raton, Florida, which has had numerous investments, both active and passive, principally in the healthcare/life-science field, but also has a substantial portfolio in general investments.
Since 1980, Dr. Abeles has also been President of MedVest, Inc., a business and financial consulting firm.
He has been instrumental in helping promulgate many early stage medical and other companies; some are still private and several have emerged into the public arena. Some of those have been acquired by major industrial and financial groups.
Dr Abeles is at present actively involved in financing, directing, advising 6 exciting biopharma companies ( A-F below):
A) He is a Founder and Chair of *BryoLogyx developing biosource pharmaceuticals and their synthetic derivatives from Stanford University to improve significantly current and future cancer immunotherapy outcomes as an adjunct to most of them, and also as a single agent with multiple immuno-oncology actions. The molecular platform also has promise in several other medical fields eg infectious disease, autoimmune conditions, neuropsychiatric disorders, inborn errors of metabolism etc
B) He recently was an early Investor in and joined the Board of *Serpin Pharma, now in clinical trials, but a substantially de-risked, small peptide company in the immuno-regulatory , autoimmune and anti-inflammatory fields. The molecular platform down regulates the inflammasome through LRP-1 agonist activity.
C) He is also a Founder/Director of a new company, *OncoLyze (novel anticancer modality through highly targeted, cancer-cell specific, membrane-porating peptides, leading to rapid cancer cell lysis ( ie “poptosis”)
D) A new biotech company *Orpheus BioScience has recently been cofounded by him. It is developing targeted biotherapeutics for specific anti-autoimmune therapies. The peptides immobilise specific and relevant autoantibodies and also delete autoreactive B cell clones.
E) Monet BioScience* is a new platform company, of which Dr Abeles is a founder Director for an novel and rapid analysis of protein-to-protein spatial interactions and rapidly deriving appropriate small molecules therefrom
F) Recently he invested in an became a director of B-Portal* a new company with a promising platform delivery-molecule to transport drugs and biologicals across the blood-brain-barrier
He was a Managing Member of ProMed Capital LLC, a New York investment group interested in Israeli medical technology venture companies. Investments included Allium* and Althera* ( now merged into AlphaTau*) in which he was a Director.
AlphaTau* has a unique alpha-particle-emitting brachytherapy for cancer, with highly promising human results and garnering much recent interest.
Other separate Israeli investments by Northlea include *Pi-Cardia, *BeatMed, *MediSense, *ViaSurgical, *NewPace, *MazeBolt, *Trendlines, *Credorax, *Amsel, *Vigor M
Dr Abeles was born in 1945 in Rhodesia (now Zimbabwe). He received his Medical degree as well as a degree in Physiology from the University of Birmingham, England, in 1969.
He practised Medicine in London, before joining the Pharmaceutical Industry in late 1971 as a Senior Medical Executive, with Sterling Drug in the UK, and then from 1973 with Pfizer Inc and Revlon Health Care in the USA.
In 1975 he became the first, full-time Wall Street health-care analyst with MD qualifications, at Kidder Peabody, until 1980 when he formed MedVest Inc and later Northlea Partners.
During this time he had a part-time, general internal medical practice in Westport, Connecticut.
Since March 1982, Dr. Abeles has been the Founder, Sole Investor and General Partner of Northlea Partners Ltd., a venture and private capital, family-office partnership headquartered in Boca Raton, Florida, which has had numerous investments, both active and passive, principally in the healthcare/life-science field, but also has a substantial portfolio in general investments.
Since 1980, Dr. Abeles has also been President of MedVest, Inc., a business and financial consulting firm.
He has been instrumental in helping promulgate many early stage medical and other companies; some are still private and several have emerged into the public arena. Some of those have been acquired by major industrial and financial groups.
Dr Abeles is at present actively involved in financing, directing, advising 6 exciting biopharma companies ( A-F below):
A) He is a Founder and Chair of *BryoLogyx developing biosource pharmaceuticals and their synthetic derivatives from Stanford University to improve significantly current and future cancer immunotherapy outcomes as an adjunct to most of them, and also as a single agent with multiple immuno-oncology actions. The molecular platform also has promise in several other medical fields eg infectious disease, autoimmune conditions, neuropsychiatric disorders, inborn errors of metabolism etc
B) He recently was an early Investor in and joined the Board of *Serpin Pharma, now in clinical trials, but a substantially de-risked, small peptide company in the immuno-regulatory , autoimmune and anti-inflammatory fields. The molecular platform down regulates the inflammasome through LRP-1 agonist activity.
C) He is also a Founder/Director of a new company, *OncoLyze (novel anticancer modality through highly targeted, cancer-cell specific, membrane-porating peptides, leading to rapid cancer cell lysis ( ie “poptosis”)
D) A new biotech company *Orpheus BioScience has recently been cofounded by him. It is developing targeted biotherapeutics for specific anti-autoimmune therapies. The peptides immobilise specific and relevant autoantibodies and also delete autoreactive B cell clones.
E) Monet BioScience* is a new platform company, of which Dr Abeles is a founder Director for an novel and rapid analysis of protein-to-protein spatial interactions and rapidly deriving appropriate small molecules therefrom
F) Recently he invested in an became a director of B-Portal* a new company with a promising platform delivery-molecule to transport drugs and biologicals across the blood-brain-barrier
He was a Managing Member of ProMed Capital LLC, a New York investment group interested in Israeli medical technology venture companies. Investments included Allium* and Althera* ( now merged into AlphaTau*) in which he was a Director.
AlphaTau* has a unique alpha-particle-emitting brachytherapy for cancer, with highly promising human results and garnering much recent interest.
Other separate Israeli investments by Northlea include *Pi-Cardia, *BeatMed, *MediSense, *ViaSurgical, *NewPace, *MazeBolt, *Trendlines, *Credorax, *Amsel, *Vigor M